Experience real-time quotes, in-depth charts, and analyst ratings

MARKET

ABBV

Abbvie Inc

NYSE

164.66

+0.41

+0.25%

After Hours: 164.66 0 0.00% 16:53 04/18 EDT

OPEN

164.96

PREV CLOSE

164.25

HIGH

167.44

LOW

164.43

VOLUME

4.48M

TURNOVER

52 WEEK HIGH

182.89

52 WEEK LOW

125.85

MARKET CAP

291.55B

P/E (TTM)

60.57

AbbVie Q1 Earnings Preview: No Repeat Of Last Year's Q1 Disappointment

AbbVie's best-selling drug, Humira, lost its patent protection in Europe in 2020 and in the U.S. In 2023. The company will announce its Q1 2024 earnings pre-market next Friday. Wall Street is projecting revenues of $11.94bn and earnings per share of $2.28. ABBV share price has grown by over 110% in the past 5 years, but only 4% over the past 12 months.

Seeking Alpha · 10h ago

Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study

Cerevel Therapeutics Holdings Inc. Released topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon in Parkinson’s disease. The trial met its primary endpoint. The drug is an adjunctive therapy to levodopa in adults.

Benzinga · 10h ago

Heard on the Street: AbbVie's Bet on a Neuroscience Drug Maker Just Got Better

AbbVie's Parkinsons disease drug performed well in a late-stage study. The drug is part of a new class of psychiatric drugs. Abbvie bought neuroscience biotech Cerevel Therapeutics in December for $8.7 billion. The Federal Trade Commission has been reviewing the deal.

The Wall Street Journal · 12h ago

AbbVie succeeds in late-stage trial for Rinvoq in inflammatory condition

AbbVie succeeds in late-stage trial for Rinvoq in inflammatory condition. Oral JAK inhibitor upadacitinib reached its main goals in a Phase 3 trial for giant cell arteritis. The company says the drug has the potential to be the first oral treatment for the condition.

Seeking Alpha · 15h ago

AbbVie Study on Treatment for Giant Cell Arteritis Meets Primary Endpoint

AbbVie says positive top-line results from a study on upadacitinib to treat adults with giant cell arteritis. The drug is approved in the U.S. To treat other inflammatory diseases. The disease causes inflammation of the arteries and generally affects people over the age of 50.

Dow Jones · 15h ago

AbbVie's Phase 3 Study Of Upadacitinib Achieves Primary Endpoint In Giant Cell Arteritis

NASDAQ · 15h ago

AbbVie Announces Phase 3 SELECT-GCA Study Of Upadacitinib Results In Patients With Giant Cell Arteritis; In Combination With A 26-week Steroid Taper Regimen Achieved Its Primary Endpoint Of Sustained Remission; Key Secondary Endpoints Were Also Met

Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis (GCA) with a 26-week steroid taper regimen achieved sustained remission from week 12 through week 52. Upadacitinib 15 mg was generally well tolerated and no new safety signals were identified in the GCA population. AbbVie is developing new treatments for patients with immune-mediated diseases. GCA is an autoimmune disease.

Benzinga · 16h ago

PHASE 3 SELECT-GCA STUDY OF UPADACITINIB (RINVOQ®) SHOWED POSITIVE RESULTS IN PATIENTS WITH GIANT CELL ARTERITIS

Reuters · 16h ago

About ABBV

AbbVie Inc. is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica, Venclexta/Venclyxto, Epkinly and Elahere; aesthetics products, which include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, which include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy and Qulipta; eye care products, which consists of Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis and Other eye care, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers.

Webull offers AbbVie Inc stock information, including NYSE: ABBV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABBV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ABBV stock methods without spending real money on the virtual paper trading platform.